Jacobio Pharmaceuticals Group Co., Ltd.
1167.HK · HKSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 95.75M | 12.63M | -394.20M | -371.86M | -0.49 |
| 2023 FY | 63.52M | 3.20M | -397.88M | -359.12M | -0.46 |
| 2024 FY | 155.71M | 155.71M | -188.17M | -155.71M | -0.20 |
| 2025 FY | 52.14M | 29.35M | -165.68M | -142.20M | -0.18 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 1.57B | 292.12M | 1.28B | 147.79M | 1.28B |
| 2023 FY | 1.46B | 387.11M | 1.14B | 209.91M | 1.07B |
| 2024 FY | 1.36B | 435.99M | 1.17B | 152.08M | 923.18M |
| 2025 FY | 1.30B | 533.92M | 943.65M | 165.24M | 770.96M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -292.42M | -16.51M | -308.92M | — | -902.83M |
| 2023 FY | -364.20M | -38.66M | -402.86M | — | -155.22M |
| 2024 FY | -74.12M | -12.09M | -86.21M | — | 207.94M |
| 2025 FY | -186.20M | -1.07M | -187.27M | — | -148.65M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 3.47B | 2.34B | — | — | — |
| 2023 FY | 2.53B | 1.60B | — | — | — |
| 2024 FY | 924.18M | -98.28M | — | — | — |
| 2025 FY | 4.43B | 3.65B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2024 Q2 | — | -14.90M | -185.89M | -169.05M | -0.22 |
| 2024 Q4 | 155.71M | 155.71M | -2.28M | 13.34M | 0.02 |
| 2025 Q2 | 45.66M | 45.66M | -67.02M | -58.99M | -0.08 |
| 2025 Q4 | 7.73M | -4.00M | -102.24M | -85.54M | -0.11 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2024 Q2 | 1.31B | 406.22M | 1.06B | 198.20M | 906.54M |
| 2024 Q4 | 1.36B | 435.99M | 1.17B | 152.08M | 923.18M |
| 2025 Q2 | 1.29B | 423.87M | 1.07B | 143.01M | 867.38M |
| 2025 Q4 | 1.30B | 533.92M | 943.65M | 165.24M | 770.96M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2024 Q2 | -180.43M | -5.48M | -185.90M | — | 361.81M |
| 2024 Q4 | 106.31M | -6.61M | 99.69M | — | -361.81M |
| 2025 Q2 | -147.53M | -186.91K | -147.72M | — | -161.23M |
| 2025 Q4 | -55.44M | -913.77K | -56.36M | — | -3.83M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2024 Q2 | 1.06B | 199.76M | — | — | — |
| 2024 Q4 | 922.00M | -100.46M | — | — | — |
| 2025 Q2 | 3.06B | 2.13B | — | — | — |
| 2025 Q4 | 4.43B | 3.65B | — | — | — |